Basic and clinical research against advanced glycation end products (AGEs): New compounds to tackle cardiovascular disease and diabetic complications

Recent Advances in Cardiovascular Drug Discovery

Volumn 10, Issue 1, 2015, Pages 10-33

  Nenna, Antonio ^a   Spadaccio, Cristiano ^b   Lusini, Mario ^a   Ulianich, Luca ^c   Chello, Massimo ^a   Nappi, Francesco ^d  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^c CNR   (Italy)

^d Centre Cardiologique du Nord   (France)

Author keywords

Advanced; Alagebrium; Diabetic cardiomyopathy; Glycosylation end products; Hydroxymethylglutaryl CoA reductase inhibitors; Pimagedine; Pyridoxamine; Thiazolidinediones

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; ALT 946; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENFOTIAMINE; BST 4997; CALCIUM CHANNEL BLOCKING AGENT; CELL SURFACE RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LR 90; METFORMIN; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRASTERONE; PYRIDOXAMINE; TENILSETAM; TETRAHYDROLIPSTATIN; THIAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOLOGICAL MARKER;

ACTIN POLYMERIZATION; AMADORI REARRANGEMENT; AUTOOXIDATION; BIOLOGICAL ACTIVITY; BLOOD GLUCOSE MONITORING; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIET THERAPY; EXTRACELLULAR MATRIX; GLYCATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LIPID PEROXIDATION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES COMPLICATIONS; DISEASE COURSE; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 84963872501     PISSN: 15748901     EISSN: 22123962     Source Type: Journal    
DOI: 10.2174/1574890110666151104120039     Document Type: Review

References (369)

1. Davidson MH, Plutzky J. The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. Am J Cardiol 2011; 108: 1b-2b.
2. Bando YK, Murohara T. Diabetes-related heart failure. Circ J 2014; 78: 576-83.
3. Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999; 22: 1186-90.
4. Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001; 24: 1620-3.
5. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation 2003; 108: 1070-7.
6. Arsov S, Graaff R, van Oeveren W, Stegmayr B, Sikole A, Rakhorst G, et al. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: A review. Clin Chem Lab Med 2014; 52: 11-20.
7. Yamagishi S, Fukami K, Matsui T. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. Int J Cardiol 2015; 185: 263-8.
8. Nowotny K, Jung T, Grune T, Hohn A. Accumulation of modified proteins and aggregate formation in aging. Exp Gerontol 2014; 57: 122-31.
9. Hodge JE. Dehydrated Foods, Chemistry of Browning Reactions in Model Systems. J Agric Food Chem 1953; 1: 928-43.
10. Davidek T, Robert F, Devaud S, Vera FA, Blank I. Sugar fragmentation in the maillard reaction cascade: formation of short-chain carboxylic acids by a new oxidative alpha-dicarbonyl cleavage pathway. J Agric Food Chem 2006; 54: 6677-84.
11. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271: 9982-6.
12. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344 Pt 1: 109-16.
13. Singh R, Barden A, Mori T, Beilin L. Advanced glycation endproducts: A review. Diabetologia 2001; 44: 129-46.
14. Rabbani N, Thornalley PJ. Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress. Biochem Soc Trans 2008; 36: 1045-50.
15. Bunn HF, Higgins PJ. Reaction of monosaccharides with proteins: Possible evolutionary significance. Science 1981; 213: 222-4.
16. Aldini G, Vistoli G, Stefek M, Chondrogianni N, Grune T, Sereikaite J, et al. Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products. Free Radic Res 2013; 47 Suppl 1: 93-137.
17. Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-A role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 1996; 27: 565-73.
18. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsiloncarboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261: 4889-94.
19. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ. Assay of advanced glycation endproducts (AGEs): Surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine-and Nepsilon-(1-carboxyethyl)lysine-modified albumin. Biochem J 2002; 364: 1-14.
20. Schmitt A, Schmitt J, Munch G, Gasic-Milencovic J. Characterization of advanced glycation end products for biochemical studies: side chain modifications and fluorescence characteristics. Anal Biochem 2005; 338: 201-15.
21. Lapolla A, Fedele D, Martano L, Arico NC, Garbeglio M, Traldi P, et al. Advanced glycation end products: A highly complex set of biologically relevant compounds detected by mass spectrometry. J Mass Spectrom 2001; 36: 370-8.
22. Sell DR, Monnier VM. Structure elucidation of a senescence crosslink from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 1989; 264: 21597-602.
23. Biemel KM, Friedl DA, Lederer MO. Identification and quantification of major maillard cross-links in human serum albumin and lens protein. Evidence for glucosepane as the dominant compound. J Biol Chem 2002; 277: 24907-15.
24. Shipanova IN, Glomb MA, Nagaraj RH. Protein modification by methylglyoxal: Chemical nature and synthetic mechanism of a major fluorescent adduct. Arch Biochem Biophys 1997; 344: 29-36.
25. Dyer DG, Dunn JA, Thorpe SR, Lyons TJ, McCance DR, Baynes JW. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. Ann N Y Acad Sci 1992; 663: 421-2.
26. Konova E, Baydanoff S, Atanasova M, Velkova A. Age-related changes in the glycation of human aortic elastin. Exp Gerontol 2004; 39: 249-54.
27. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-8.
28. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998; 47: 945-52.
29. Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. Faseb J 2003; 17: 1289-91.
30. Satoh H, Togo M, Hara M, Miyata T, Han K, Maekawa H, et al. Advanced glycation endproducts stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells. Biochem Biophys Res Commun 1997; 239: 111-5.
31. David KC, Scott RH, Nixon GF. Advanced glycation endproducts induce a proliferative response in vascular smooth muscle cells via altered calcium signaling. Biochem Pharmacol 2008; 76: 1110-20.
32. Soro-Paavonen A, Zhang WZ, Venardos K, Coughlan MT, Harris E, Tong DC, et al. Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens 2010; 28: 780-8.
33. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005; 289: F420-30.
34. Wu L, Juurlink BH. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 2002; 39: 809-14.
35. Grimm S, Ott C, Horlacher M, Weber D, Hohn A, Grune T. Advanced-glycation-end-product-induced formation of immunoproteasomes: Involvement of RAGE and Jak2/STAT1. Biochem J 2012; 448: 127-39.
36. Jung T, Catalgol B, Grune T. The proteasomal system. Mol Aspects Med 2009; 30: 191-296.
37. Zeng J, Dunlop RA, Rodgers KJ, Davies MJ. Evidence for inactivation of cysteine proteases by reactive carbonyls via glycation of active site thiols. Biochem J 2006; 398: 197-206.
38. Stolzing A, Widmer R, Jung T, Voss P, Grune T. Degradation of glycated bovine serum albumin in microglial cells. Free Radic Biol Med 2006; 40: 1017-27.
39. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11704-8.
40. Witztum JL. The role of oxidized LDL in atherosclerosis. Adv Exp Med Biol 1991; 285: 353-65.
41. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 1993; 90: 6434-8.
42. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995; 270: 10828-32.
43. Vlassara H, Bucala R. Recent progress in advanced glycation and diabetic vascular disease: Role of advanced glycation end product receptors. Diabetes 1996; 45 Suppl 3: S65-6.
44. Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol 2014; 2: 411-29.
45. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-5004.
46. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-403.
47. Falcone C, Bozzini S, D'Angelo A, Matrone B, Colonna A, Benzi A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: Possible correlation with clinical presentation. Dis Markers 2013; 35: 135-40.
48. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, et al. RAGE: A novel cellular receptor for advanced glycation end products. Diabetes 1996; 45 Suppl 3: S77-80.
49. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097-109.
50. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008; 283: 35507-16.
51. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83: 876-86.
52. Koyama H, Tanaka S, Monden M, Shoji T, Morioka T, Fukumoto S, et al. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: Randomized controlled trial (PioRAGE). Atherosclerosis 2014; 234: 329-34.
53. Guimaraes EL, Empsen C, Geerts A, van Grunsven LA. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol 2010; 52: 389-97.
54. Wong A, Dukic-Stefanovic S, Gasic-Milenkovic J, Schinzel R, Wiesinger H, Riederer P, et al. Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. Eur J Neurosci 2001; 14: 1961-7.
55. San Martin A, Foncea R, Laurindo FR, Ebensperger R, Griendling KK, Leighton F. Nox1-based NADPH oxidase-derived superoxide is required for VSMC activation by advanced glycation endproducts. Free Radic Biol Med 2007; 42: 1671-9.
56. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009; 46: 572-80.
57. Yagame M, Kim Y, Zhu D, Suzuki D, Eguchi K, Nomoto Y, et al. Differential distribution of type IV collagen chains in patients with diabetic nephropathy in non-insulin-dependent diabetes mellitus. Nephron 1995; 70: 42-8.
58. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 2001; 81: 102-13.
59. Huang CY, Lai KY, Hung LF, Wu WL, Liu FC, Ho LJ. Advanced glycation end products cause collagen II reduction by activating Janus kinase/signal transducer and activator of transcription 3 pathway in porcine chondrocytes. Rheumatology (Oxford) 2011; 50: 1379-89.
60. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-808.
61. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997; 272: 16498-506.
62. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
63. Berbaum K, Shanmugam K, Stuchbury G, Wiede F, Korner H, Munch G. Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array. Cytokine 2008; 41: 198-203.
64. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 2000; 49: 1561-70.
65. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011; 46: 217-24.
66. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997; 96: 2262-71.
67. Chawla D, Bansal S, Banerjee BD, Madhu SV, Kalra OP, Tripathi AK. Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications. Microvasc Res 2014; 95: 1-6.
68. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009; 52: 2251-63.
69. Lin J, Tang Y, Kang Q, Feng Y, Chen A. Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARgamma activity and attenuating oxidative stress. Br J Pharmacol 2012; 166: 2212-27.
70. Tang Y, Chen A. Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Invest 2014; 94: 503-16.
71. Nah SS, Choi IY, Lee CK, Oh JS, Kim YG, Moon HB, et al. Effects of advanced glycation end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes. Rheumatology (Oxford) 2008; 47: 425-31.
72. Alikhani M, Maclellan CM, Raptis M, Vora S, Trackman PC, Graves DT. Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. Am J Physiol Cell Physiol 2007; 292: C850-6.
73. Hu P, Lai D, Lu P, Gao J, He H. ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. Int J Mol Med 2012; 29: 613-8.
74. Wei Q, Ren X, Jiang Y, Jin H, Liu N, Li J. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress. BMC Cardiovasc Disord 2013; 13: 13.
75. Ko SY, Lin IH, Shieh TM, Ko HA, Chen HI, Chi TC, et al. Cell hypertrophy and MEK/ERK phosphorylation are regulated by glyceraldehyde-derived AGEs in cardiomyocyte H9c2 cells. Cell Biochem Biophys 2013; 66: 537-44.
76. Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004; 66: 2137-47.
77. Shaw SS, Schmidt AM, Banes AK, Wang X, Stern DM, Marrero MB. S100B-RAGE-mediated augmentation of angiotensin IIinduced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes 2003; 52: 2381-8.
78. Serban AI, Stanca L, Geicu OI, Munteanu MC, Costache M, Dinischiotu A. Extracellular matrix is modulated in advanced glycation end products milieu via a RAGE receptor dependent pathway boosted by transforming growth factor-beta1 RAGE. J Diabetes 2015; 7: 114-24.
79. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143: 1699-712.
80. Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A. Downregulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 2005; 26: 293-301.
81. Al-Robaiy S, Weber B, Simm A, Diez C, Rolewska P, Silber RE, et al. The receptor for advanced glycation end-products supports lung tissue biomechanics. Am J Physiol Lung Cell Mol Physiol 2013; 305: L491-500.
82. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Tolllike receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487-96.
83. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198: 1507-15.
84. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
85. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ, Jr., et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001; 21: 905-10.
86. Rong LL, Trojaborg W, Qu W, Kostov K, Yan SD, Gooch C, et al. Antagonism of RAGE suppresses peripheral nerve regeneration. Faseb J 2004; 18: 1812-7.
87. Brisslert M, Amu S, Pullerits R. Intra-peritoneal sRAGE treatment induces alterations in cellular distribution of CD19(+), CD3 (+) and Mac-1 (+) cells in lymphoid organs and peritoneal cavity. Cell Tissue Res 2013; 351: 139-48.
88. Meghnani V, Vetter SW, Leclerc E. RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line. Biochim Biophys Acta 2014; 1842: 1017-27.
89. Wagner NB, Weide B, Reith M, Tarnanidis K, Kehrel C, Lichtenberger R, et al. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. Int J Cancer 2015; 137: 2607-17.
90. Giron-Gonzalez MD, Morales-Portillo A, Salinas-Castillo A, Lopez-Jaramillo FJ, Hernandez-Mateo F, Santoyo-Gonzalez F, et al. Engineered glycated amino dendritic polymers as specific nonviral gene delivery vectors targeting the receptor for advanced glycation end products. Bioconjug Chem 2014; 25: 1151-61.
91. Yamagishi S, Nakamura K, Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPARgamma agonists and its implication in cardiovascular disease. Pharmacol Res 2009; 60: 174-8.
92. Yang Q, Chen C, Wu S, Zhang Y, Mao X, Wang W. Advanced glycation end products downregulates peroxisome proliferatoractivated receptor gamma expression in cultured rabbit chondrocyte through MAPK pathway. Eur J Pharmacol 2010; 649: 108-14.
93. Chen YJ, Sheu ML, Tsai KS, Yang RS, Liu SH. Advanced glycation end products induce peroxisome proliferator-activated receptor gamma down-regulation-related inflammatory signals in human chondrocytes via Toll-like receptor-4 and receptor for advanced glycation end products. PLoS One 2013; 8: e66611.
94. Kahn BB, McGraw TE. Rosiglitazone, PPAR gamma, and type 2 diabetes. N Engl J Med 2010; 363: 2667-9.
95. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex. Mol Med 1995; 1: 634-46.
96. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996; 93: 11047-52.
97. Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A 2004; 101: 11767-72.
98. Cai W, He JC, Zhu L, Lu C, Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 2006; 103: 13801-6.
99. Cai W, He JC, Zhu L, Chen X, Striker GE, Vlassara H. AGEreceptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am J Physiol Cell Physiol 2008; 294: C145-52.
100. Hodgkinson CP, Mander A, Sale GJ. Identification of 80K-H as a protein involved in GLUT4 vesicle trafficking. Biochem J 2005; 388: 785-93.
101. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002; 277: 6852-7.
102. Lee YM, Lee JB. Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma. J Int Med Res 2013; 41: 825-34.
103. Pricci F, Leto G, Amadio L, Iacobini C, Romeo G, Cordone S, et al. Role of galectin-3 as a receptor for advanced glycosylation end products. Kidney Int Suppl 2000; 77: S31-9.
104. Mercer N, Ahmed H, McCarthy AD, Etcheverry SB, Vasta GR, Cortizo AM. AGE-R3/galectin-3 expression in osteoblast-like cells: Regulation by AGEs. Mol Cell Biochem 2004; 266: 17-24.
105. Menini S, Iacobini C, Ricci C, Blasetti Fantauzzi C, Salvi L, Pesce CM, et al. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res 2013; 100: 472-80.
106. Pugliese G, Iacobini C, Pesce CM, Menini S. Galectin-3: An emerging all-out player in metabolic disorders and their complications. Glycobiology 2015; 25: 136-50.
107. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, et al. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 1995; 230: 408-15.
108. Ohgami N, Nagai R, Miyazaki A, Ikemoto M, Arai H, Horiuchi S, et al. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 2001; 276: 13348-55.
109. Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S, et al. Cd36, A member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem 2001; 276: 3195-202.
110. Ohgami N, Nagai R, Ikemoto M, Arai H, Miyazaki A, Hakamata H, et al. CD36, serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complications 2002; 16: 56-9.
111. Jono T, Miyazaki A, Nagai R, Sawamura T, Kitamura T, Horiuchi S. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett 2002; 511: 170-4.
112. Tamura Y, Adachi H, Osuga J, Ohashi K, Yahagi N, Sekiya M, et al. FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J Biol Chem 2003; 278: 12613-7.
113. Freeman M, Ekkel Y, Rohrer L, Penman M, Freedman NJ, Chisolm GM, et al. Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: Lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1991; 88: 4931-5.
114. Wang Z, Jiang Y, Liu N, Ren L, Zhu Y, An Y, et al. Advanced glycation end-product Nepsilon-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012; 221: 387-96.
115. Miyazaki A, Nakayama H, Horiuchi S. Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc Med 2002; 12: 258-62.
116. Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003; 25: 283-92.
117. Grimm S, Ernst L, Grotzinger N, Hohn A, Breusing N, Reinheckel T, et al. Cathepsin D is one of the major enzymes involved in intracellular degradation of AGE-modified proteins. Free Radic Res 2010; 44: 1013-26.
118. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/-mice despite severe hypercholesterolemia. Atherosclerosis 2008; 198: 39-48.
119. Shiu SW, Wong Y, Tan KC. Effect of advanced glycation end products on lectin-like oxidized low density lipoprotein receptor-1 expression in endothelial cells. J Atheroscler Thromb 2012; 19: 1083-92.
120. Adachi H, Tsujimoto M. FEEL-1, a novel scavenger receptor with in vitro bacteria-binding and angiogenesis-modulating activities. J Biol Chem 2002; 277: 34264-70.
121. Sell DR, Monnier VM. Molecular basis of arterial stiffening: Role of glycation-A mini-review. Gerontology 2012; 58: 227-37.
122. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996; 39: 946-51.
123. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104: 1464-70.
124. Verzijl N, DeGroot J, Ben ZC, Brau-Benjamin O, Maroudas A, Bank RA, et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: A possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum 2002; 46: 114-23.
125. Greenwald SE. Ageing of the conduit arteries. J Pathol 2007; 211: 157-72.
126. McNulty M, Mahmud A, Feely J. Advanced glycation endproducts and arterial stiffness in hypertension. Am J Hypertens 2007; 20: 242-7.
127. McCarthy AD, Etcheverry SB, Bruzzone L, Lettieri G, Barrio DA, Cortizo AM. Non-enzymatic glycosylation of a type I collagen matrix: Effects on osteoblastic development and oxidative stress. BMC Cell Biol 2001; 2: 16.
128. Pozzi A, Zent R, Chetyrkin S, Borza C, Bulus N, Chuang P, et al. Modification of collagen IV by glucose or methylglyoxal alters distinct mesangial cell functions. J Am Soc Nephrol 2009; 20: 2119-25.
129. Schalkwijk CG, Miyata T. Early-and advanced non-enzymatic glycation in diabetic vascular complications: The search for therapeutics. Amino Acids 2012; 42: 1193-204.
130. Haucke E, Navarrete-Santos A, Simm A, Silber RE, Hofmann B. Glycation of extracellular matrix proteins impairs migration of immune cells. Wound Repair Regen 2014; 22: 239-45.
131. Charonis AS, Reger LA, Dege JE, Kouzi-Koliakos K, Furcht LT, Wohlhueter RM, et al. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1990; 39: 807-14.
132. Hammes HP, Weiss A, Hess S, Araki N, Horiuchi S, Brownlee M, et al. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest 1996; 75: 325-38.
133. Nowotny K, Grune T. Degradation of oxidized and glycoxidized collagen: Role of collagen cross-linking. Arch Biochem Biophys 2014; 542: 56-64.
134. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003; 14: 728-31.
135. Cai W, He JC, Zhu L, Peppa M, Lu C, Uribarri J, et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004; 110: 285-91.
136. Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: Potential role of AGER1 and SIRT1. Diabetes Care 2011; 34: 1610-6.
137. Gugliucci A, Kotani K, Taing J, Matsuoka Y, Sano Y, Yoshimura M, et al. Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Ann Nutr Metab 2009; 54: 197-201.
138. Yoshikawa T, Miyazaki A, Fujimoto S. Decrease in serum levels of advanced glycation end-products by short-term lifestyle modification in non-diabetic middle-aged females. Med Sci Monit 2009; 15: Ph65-73.
139. Hamada Y, Odagaki Y, Sakakibara F, Naruse K, Koh N, Hotta N. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients. Life Sci 1995; 57: 23-9.
140. Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, et al. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 2000; 23: 1539-44.
141. Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, et al. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine. J Diabetes Complications 2010; 24: 424-32.
142. Li YM, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, et al. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 1996; 93: 3902-7.
143. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 31-40.
144. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 1986; 232: 1629-32.
145. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88: 11555-8.
146. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocininduced diabetic rat. Diabetes 1991; 40: 1328-34.
147. Edelstein D, Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 1992; 35: 96-7.
148. Huijberts MS, Wolffenbuttel BH, Boudier HA, Crijns FR, Kruseman AC, Poitevin P, et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993; 92: 1407-11.
149. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994; 43: 676-83.
150. Miyauchi Y, Shikama H, Takasu T, Okamiya H, Umeda M, Hirasaki E, et al. Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats. Eur J Endocrinol 1996; 134: 467-73.
151. Schmidt RE, Dorsey DA, Beaudet LN, Reiser KM, Williamson JR, Tilton RG. Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats with streptozocin-induced diabetes. Diabetes 1996; 45: 284-90.
152. Yamauchi A, Takei I, Makita Z, Nakamoto S, Ohashi N, Kiguchi H, et al. Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats. Diabetes Res Clin Pract 1997; 34: 127-33.
153. Degenhardt TP, Fu MX, Voss E, Reiff K, Neidlein R, Strein K, et al. Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats. Diabetes Res Clin Pract 1999; 43: 81-9.
154. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001; 50: 1636-42.
155. Birrell AM, Heffernan SJ, Kirwan P, McLennan S, Gillin AG, Yue DK. The effects of aminoguanidine on renal changes in a baboon model of Type 1 diabetes. J Diabetes Complications 2002; 16: 301-9.
156. Chang KC, Tseng CD, Wu MS, Liang JT, Tsai MS, Cho YL, et al. Aminoguanidine prevents arterial stiffening in a new rat model of type 2 diabetes. Eur J Clin Invest 2006; 36: 528-35.
157. Chang KC, Hsu KL, Tseng CD, Lin YD, Cho YL, Tseng YZ. Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats. Br J Pharmacol 2006; 147: 944-50.
158. Chang KC, Tseng CD, Chou TF, Cho YL, Chi TC, Su MJ, et al. Arterial stiffening and cardiac hypertrophy in a new rat model of type 2 diabetes. Eur J Clin Invest 2006; 36: 1-7.
159. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992; 41: 552-6.
160. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, et al. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation endproduct formation. Diabetes 1993; 42: 221-32.
161. Hasan K, Heesen BJ, Corbett JA, McDaniel ML, Chang K, Allison W, et al. Inhibition of nitric oxide formation by guanidines. Eur J Pharmacol 1993; 249: 101-6.
162. Laszlo F, Evans SM, Whittle BJ. Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo. Eur J Pharmacol 1995; 272: 169-75.
163. Nilsson BO. Biological effects of aminoguanidine: An update. Inflamm Res 1999; 48: 509-15.
164. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40.
165. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999; 20: 493-510.
166. Suji G, Sivakami S. DNA damage by free radical production by aminoguanidine. Ann N Y Acad Sci 2006; 1067: 191-9.
167. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 2005; 1: 287-98.
168. Kousar S, Sheikh MA, Asghar M. Antiglycation activity of thiamin-HCl and benfotiamine in diabetic condition. J Pak Med Assoc 2012; 62: 1033-8.
169. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-20.
170. Rabbani N, Alam SS, Riaz S, Larkin JR, Akhtar MW, Shafi T, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: A randomised, double-blind placebocontrolled pilot study. Diabetologia 2009; 52: 208-12.
171. Nascimento MM, Suliman ME, Murayama Y, Nihi M, Hayashi SY, Stenvinkel P, et al. Effect of high-dose thiamine and pyridoxine on advanced glycation end products and other oxidative stress markers in hemodialysis patients: A randomized placebo-controlled study. J Ren Nutr 2006; 16: 119-24.
172. Stracke H, Hammes HP, Werkmann D, Mavrakis K, Bitsch I, Netzel M, et al. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 2001; 109: 330-6.
173. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-9.
174. Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A. The multifaceted therapeutic potential of benfotiamine. Pharmacol Res 2010; 61: 482-8.
175. Balakumar P, Chakkarwar VA, Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem 2009; 320: 149-62.
176. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, et al. Benfotiamine prevents macro-and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29: 2064-71.
177. Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, et al. A double-blind, randomized, placebocontrolled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010; 33: 1598-601.
178. Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, Heeringa P, et al. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One 2012; 7: e40427.
179. Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, Seljeflot I, et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: A 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 2012; 35: 1095-7.
180. Booth AA, Khalifah RG, Hudson BG. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: Comparison with aminoguanidine. Biochem Biophys Res Commun 1996; 220: 113-9.
181. Booth AA, Khalifah RG, Todd P, Hudson BG. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 1997; 272: 5430-7.
182. Voziyan PA, Khalifah RG, Thibaudeau C, Yildiz A, Jacob J, Serianni AS, et al. Modification of proteins in vitro by physiological levels of glucose: Pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J Biol Chem 2003; 278: 46616-24.
183. Chetyrkin SV, Mathis ME, Ham AJ, Hachey DL, Hudson BG, Voziyan PA. Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: Inhibition by pyridoxamine. Free Radic Biol Med 2008; 44: 1276-85.
184. Adrover M, Vilanova B, Frau J, Munoz F, Donoso J. The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect. Bioorg Med Chem 2008; 16: 5557-69.
185. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000; 275: 21177-84.
186. Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem 2003; 278: 42012-9.
187. Voziyan PA, Metz TO, Baynes JW, Hudson BG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 2002; 277: 3397-403.
188. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005; 62: 1671-81.
189. Voziyan PA, Hudson BG. Pyridoxamine: The many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci 2005; 1043: 807-16.
190. Ahmad S, Shahab U, Baig MH, Khan MS, Khan MS, Srivastava AK, et al. Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation endproducts. PLoS One 2013; 8: e72128.
191. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-50.
192. Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003; 63: 2123-33.
193. Chang KC, Liang JT, Tsai PS, Wu MS, Hsu KL. Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen. Br J Pharmacol 2009; 157: 1419-26.
194. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007; 27: 605-14.
195. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012; 23: 131-6.
196. Sobal G, Menzel J. The role of antioxidants in the long-term glycation of low density lipoprotein and its Cu2+-catalyzed oxidation. Free Radic Res 2000; 32: 439-49.
197. Gomez-Perez FJ, Valles-Sanchez VE, Lopez-Alvarenga JC, Choza-Romero R, Ibarra Pascuali JJ, Gonzalez Orellana R, et al. Vitamin E modifies neither fructosamine nor HbA1c levels in poorly controlled diabetes. Rev Invest Clin 1996; 48: 421-4.
198. Reaven PD, Herold DA, Barnett J, Edelman S. Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care 1995; 18: 807-16.
199. Lu L, Erhard P, Salomon RG, Weiss MF. Serum vitamin E and oxidative protein modification in hemodialysis: A randomized clinical trial. Am J Kidney Dis 2007; 50: 305-13.
200. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 1999; 58: 1765-73.
201. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003; 29: 6s95-103.
202. Sena CM, Matafome P, Louro T, Nunes E, Fernandes R, Seica RM. Metformin restores endothelial function in aorta of diabetic rats. Br J Pharmacol 2011; 163: 424-37.
203. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999; 48: 198-202.
204. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Aessopos A, Paterakis T, Katsikis I, et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism 2007; 56: 129-34.
205. Rabbani N, Chittari MV, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 2010; 59: 1038-45.
206. Faure P, Wiernsperger N, Polge C, Favier A, Halimi S. Impairment of the antioxidant properties of serum albumin in patients with diabetes: Protective effects of metformin. Clin Sci (Lond) 2008; 114: 251-6.
207. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Teerlink T, Gram J, et al. Impact of metformin versus repaglinide on nonglycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008; 158: 631-41.
208. Engelen L, Lund SS, Ferreira I, Tarnow L, Parving HH, Gram J, et al. Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. Eur J Endocrinol 2011; 164: 371-9.
209. Kanazawa I, Yamamoto M, Yamaguchi T, Sugimoto T. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 362-5.
210. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000; 301: 65-77.
211. Tan KC, Chow WS, Tso AW, Xu A, Tse HF, Hoo RL, et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 2007; 50: 1819-25.
212. Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, et al. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 2006; 317: 37-43.
213. Liang C, Ren Y, Tan H, He Z, Jiang Q, Wu J, et al. Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products. Br J Pharmacol 2009; 158: 1865-73.
214. Oz Gul O, Tuncel E, Yilmaz Y, Ulukaya E, Gul CB, Kiyici S, et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabolism 2010; 59: 64-9.
215. Matsui T, Nishino Y, Takeuchi M, Yamagishi S. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 2011; 63: 383-8.
216. Nakashima S, Matsui T, Takeuchi M, Yamagishi SI. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res 2014; 46: 717-21.
217. Jung E, Kim J, Kim SH, Kim S, Cho MH. Gemigliptin, A novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. Eur J Pharmacol 2014; 744: 98-102.
218. Ahmed N, Babaei-Jadidi R, Howell SK, Thornalley PJ, Beisswenger PJ. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 2005; 28: 2465-71.
219. Sakharova OV, Lleva RR, Dziura JD, Spollett GR, Howell SK, Beisswenger PJ, et al. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents. J Diabetes Complications 2012; 26: 333-8.
220. Lyons TJ, Bailie KE, Dyer DG, Dunn JA, Baynes JW. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 1991; 87: 1910-5.
221. Salmela PI, Oikarinen AI, Ukkola O, Karjalainen A, Linnaluoto M, Puukka R, et al. Improved metabolic control in patients with noninsulin-dependent diabetes mellitus is associated with a slower accumulation of glycation products in collagen. Eur J Clin Invest 1995; 25: 494-500.
222. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: Relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999; 48: 870-80.
223. Chiarelli F, de Martino M, Mezzetti A, Catino M, Morgese G, Cuccurullo F, et al. Advanced glycation end products in children and adolescents with diabetes: Relation to glycemic control and early microvascular complications. J Pediatr 1999; 134: 486-91.
224. Schiel R, Franke S, Appel T, Voigt U, Ross IS, Kientsch-Engel R, et al. Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN). J Diabetes Complications 2003; 17: 90-7.
225. Schiel R, Franke S, Appel T, Voigt U, Ross IS, Kientsch-Engel R, et al. Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: Results from a 10 yearprospective, population-based survey on the quality of diabetes care in Germany (JEVIN). Eur J Med Res 2004; 9: 391-9.
226. Jaleel A, Halvatsiotis P, Williamson B, Juhasz P, Martin S, Nair KS. Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. Diabetes Care 2005; 28: 645-52.
227. Yu Y, Thorpe SR, Jenkins AJ, Shaw JN, Sochaski MA, McGee D, et al. Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia 2006; 49: 2488-98.
228. Mentink CJ, Kilhovd BK, Rondas-Colbers GJ, Torjesen PA, Wolffenbuttel BH. Time course of specific AGEs during optimised glycaemic control in type 2 diabetes. Neth J Med 2006; 64: 10-6.
229. Norlinah MI, Hamizah R, Md Isa SH, Wan Nazaimoon WM, Khalid BA. The effects of short-term, rapid glycemic control on the peroneal nerve function and serum VCAM-1 and AGE in type 2 diabetic patients in Malaysia. Indian J Med Sci 2009; 63: 131-8.
230. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
231. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
232. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-87.
233. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 3274-82.
234. Miyata T, van Ypersele de Strihou C. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: Implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch Biochem Biophys 2003; 419: 50-4.
235. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212-22.
236. Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME. The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl 2004: S105-7.
237. Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-20.
238. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005; 16: 2976-84.
239. Izuhara Y, Sada T, Yanagisawa H, Koike H, Ohtomo S, Dan T, et al. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler Thromb Vasc Biol 2008; 28: 1767-73.
240. Liu XP, Pang YJ, Zhu WW, Zhao TT, Zheng M, Wang YB, et al. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Clin Exp Pharmacol Physiol 2009; 36: 287-96.
241. Tian S, Ge X, Wu K, Yang H, Liu Y. Ramipril protects the endothelium from high glucose-induced dysfunction through CaMKKbeta/AMPK and heme oxygenase-1 activation. J Pharmacol Exp Ther 2014; 350: 5-13.
242. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005; 16: 2363-72.
243. Sebekova K, Lill M, Boor P, Heidland A, Amann K. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system. Am J Nephrol 2009; 29: 164-70.
244. Sebekova K, Gazdikova K, Syrova D, Blazicek P, Schinzel R, Heidland A, et al. Effects of ramipril in nondiabetic nephropathy: Improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 2003; 17: 265-70.
245. Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: A fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 2012; 61: 549-59.
246. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007; 7: 463-9.
247. Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Inoue H. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptorgammaactivation. Protein Pept Lett 2008; 15: 850-3.
248. Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010; 61: 34-9.
249. Monacelli F, Poggi A, Storace D, Durante A, Traverso N, Viviani GL, et al. Effects of valsartan therapy on protein glycoxidation. Metabolism 2006; 55: 1619-24.
250. Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 2006; 74: 201-3.
251. Komiya N, Hirose H, Saisho Y, Saito I, Itoh H. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. Int Heart J 2008; 49: 681-9.
252. Mitsuhashi H, Tamura K, Yamauchi J, Ozawa M, Yanagi M, Dejima T, et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009; 207: 186-90.
253. Hartog JW, van de Wal RM, Schalkwijk CG, Miyata T, Jaarsma W, Plokker HW, et al. Advanced glycation end-products, antihypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. Eur J Heart Fail 2010; 12: 397-403.
254. Honda H, Hosaka N, Aoshima Y, Hirai Y, Michihata T, Akizawa T. Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients. Clin Exp Hypertens 2012; 34: 17-23.
255. Saha SA, LaSalle BK, Clifton GD, Short RA, Tuttle KR. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease-a dose-response relationship study. Am J Ther 2010; 17: 553-8.
256. Ono Y, Mizuno K, Takahashi M, Miura Y, Watanabe T. Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. Fukushima J Med Sci 2013; 59: 69-75.
257. Rabbani N, Adaikalakoteswari A, Rossing K, Rossing P, Tarnow L, Parving HH, et al. Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. Amino Acids 2012; 42: 1627-39.
258. Engelen L, Persson F, Ferreira I, Rossing P, Hovind P, Teerlink T, et al. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl) lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. Nephrol Dial Transplant 2011; 26: 3573-7.
259. Busch M, Franke S, Wolf G, Rohde RD, Stein G. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract 2008; 108: c291-7.
260. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Koide H, Ueda Y, et al. Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. Clin Cardiol 2011; 34: 372-7.
261. Yamagishi S, Takeuchi M, Inoue H. Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats. Int J Tissue React 2005; 27: 137-43.
262. Kesavan SK, Bhat S, Golegaonkar SB, Jagadeeshaprasad MG, Deshmukh AB, Patil HS, et al. Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hydralazine mediated transglycation. Sci Rep 2013; 3: 2941.
263. Mehta R, Wong L, O'Brien PJ. Cytoprotective mechanisms of carbonyl scavenging drugs in isolated rat hepatocytes. Chem Biol Interact 2009; 178: 317-23.
264. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271-80.
265. Sezer ED, Sozmen EY, Nart D, Onat T. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc Health Risk Manag 2011; 7: 333-43.
266. Mihos CG, Pineda AM, Santana O. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res 2014; 88: 12-9.
267. Satoh M, Takahashi Y, Tabuchi T, Minami Y, Tamada M, Takahashi K, et al. Cellular and molecular mechanisms of statins: an update on pleiotropic effects. Clin Sci (Lond) 2015; 129: 93-105.
268. Jinnouchi Y, Yamagishi S, Takeuchi M, Ishida S, Jinnouchi Y, Jinnouchi J, et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006; 6: 191-3.
269. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Takeuchi M, Maeda S, et al. Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Oxid Med Cell Longev 2010; 3: 304-7.
270. Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: Clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-7.
271. Akira K, Amano M, Okajima F, Hashimoto T, Oikawa S. Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits. Biol Pharm Bull 2006; 29: 75-81.
272. Ishibashi Y, Yamagishi S, Matsui T, Ohta K, Tanoue R, Takeuchi M, et al. Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism 2012; 61: 1067-72.
273. Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010; 209: 173-7.
274. Mahajan N, Bahl A, Dhawan V. C-reactive protein (CRP) upregulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol 2010; 142: 273-8.
275. Yoon SJ, Yoon YW, Lee BK, Kwon HM, Hwang KC, Kim M, et al. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med 2009; 41: 802-11.
276. Li YB, Yin JJ, Wang HJ, Wang J, Tian H, Yang M. Effect of simvastatin on expression of transforming growth factor-beta and collagen type IV in rat mesangial cells. Pharmacology 2011; 88: 188-92.
277. Paradela-Dobarro B, Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L, Garcia-Acuna JM, Aguiar-Souto P, et al. Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: Evidence in patients with acute myocardial infarction. Eur J Pharm Sci 2013; 49: 512-8.
278. Calkin AC, Giunti S, Sheehy KJ, Chew C, Boolell V, Rajaram YS, et al. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 2008; 51: 1731-40.
279. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, et al. Suppression of RAGE as a basis of simvastatindependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26: 2716-23.
280. Scharnagl H, Stojakovic T, Winkler K, Rosinger S, Marz W, Boehm BO. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2007; 115: 372-5.
281. Malik NS, Meek KM. The inhibition of sugar-induced structural alterations in collagen by aspirin and other compounds. Biochem Biophys Res Commun 1994; 199: 683-6.
282. Urios P, Grigorova-Borsos AM, Sternberg M. Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Res Clin Pract 2007; 77: 337-40.
283. Contreras I, Reiser KM, Martinez N, Giansante E, Lopez T, Suarez N, et al. Effects of aspirin or basic amino acids on collagen crosslinks and complications in NIDDM. Diabetes Care 1997; 20: 832-5.
284. Wu J, Zhao MY, Zheng H, Zhang H, Jiang Y. Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression. Acta Pharmacol Sin 2010; 31: 1367-75.
285. Diamanti-Kandarakis E, Piperi C, Alexandraki K, Katsilambros N, Kouroupi E, Papailiou J, et al. Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism 2006; 55: 494-500.
286. Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 66: 103-9.
287. Diamanti-Kandarakis E, Piperi C, Alexandraki KI, Papailiou J, Ekonomou F, Koulouri E, et al. The acute effect of Orlistat on dietary glycotoxins in diabetics and healthy women. Minerva Endocrinol 2009; 34: 97-104.
288. Aragno M, Mastrocola R, Medana C, Catalano MG, Vercellinatto I, Danni O, et al. Oxidative stress-dependent impairment of cardiacspecific transcription factors in experimental diabetes. Endocrinology 2006; 147: 5967-74.
289. Brignardello E, Runzo C, Aragno M, Catalano MG, Cassader M, Perin PC, et al. Dehydroepiandrosterone administration counteracts oxidative imbalance and advanced glycation end product formation in type 2 diabetic patients. Diabetes Care 2007; 30: 2922-7.
290. Aragno M, Mastrocola R, Alloatti G, Vercellinatto I, Bardini P, Geuna S, et al. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology 2008; 149: 380-8.
291. Aragno M, Meineri G, Vercellinatto I, Bardini P, Raimondo S, Peiretti PG, et al. Cardiac impairment in rabbits fed a high-fat diet is counteracted by dehydroepiandrosterone supplementation. Life Sci 2009; 85: 77-84.
292. Kageyama Y, Takahashi M, Ichikawa T, Torikai E, Nagano A. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 73-80.
293. Kageyama Y, Takahashi M, Nagafusa T, Torikai E, Nagano A. Methotrexate reduces the levels of pentosidine and 8-hydroxydeoxy guanosine in patients with rheumatoid arthritis. Mod Rheumatol 2007; 17: 398-402.
294. Kageyama Y, Takahashi M, Nagafusa T, Torikai E, Nagano A. Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int 2008; 28: 245-51.
295. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998; 9: 2349-56.
296. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997; 46: 895-9.
297. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999; 42: 579-88.
298. Miyata T, Ueda Y, Asahi K, Izuhara Y, Inagi R, Saito A, et al. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 2000; 11: 1719-25.
299. Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001; 276: 48967-72.
300. Mizutani K, Ikeda K, Tsuda K, Yamori Y. Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J Hypertens 2002; 20: 1607-14.
301. Nakamura S, Tachikawa T, Tobita K, Aoyama I, Takayama F, Enomoto A, et al. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats. Am J Kidney Dis 2003; 41: S68-71.
302. Wada R, Nishizawa Y, Yagihashi N, Takeuchi M, Ishikawa Y, Yasumura K, et al. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001; 31: 513-20.
303. Khalifah RG, Chen Y, Wassenberg JJ. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: A rational approach to second-generation Amadorin design. Ann NY Acad Sci 2005; 1043: 793-806.
304. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001; 44: 108-14.
305. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 2002; 51: 3283-9.
306. Dukic-Stefanovic S, Schinzel R, Riederer P, Munch G. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology 2001; 2: 19-34.
307. Munch G, Mayer S, Michaelis J, Hipkiss AR, Riederer P, Muller R, et al. Influence of advanced glycation end-products and AGEinhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim Biophys Acta 1997; 1360: 17-29.
308. Munch G, Taneli Y, Schraven E, Schindler U, Schinzel R, Palm D, et al. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm Park Dis Dement Sect 1994; 8: 193-208.
309. Figarola JL, Scott S, Loera S, Tessler C, Chu P, Weiss L, et al. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 2003; 46: 1140-52.
310. Figarola JL, Shanmugam N, Natarajan R, Rahbar S. Antiinflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 2007; 56: 647-55.
311. Bhatwadekar A, Glenn JV, Figarola JL, Scott S, Gardiner TA, Rahbar S, et al. A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br J Ophthalmol 2008; 92: 545-7.
312. Satheesan S, Figarola JL, Dabbs T, Rahbar S, Ermel R. Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis. Br J Pharmacol 2014; 171: 3103-14.
313. Takizawa S, Izuhara Y, Kitao Y, Hori O, Ogawa S, Morita Y, et al. A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia. Brain Res 2007; 1183: 124-37.
314. Izuhara Y, Nangaku M, Takizawa S, Takahashi S, Shao J, Oishi H, et al. A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant 2008; 23: 497-509.
315. Guo Q, Mori T, Jiang Y, Hu C, Osaki Y, Yoneki Y, et al. Methylglyoxal contributes to the development of insulin resistance and salt sensitivity in Sprague-Dawley rats. J Hypertens 2009; 27: 1664-71.
316. Hipkiss AR, Chana H. Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem Biophys Res Commun 1998; 248: 28-32.
317. Hipkiss AR, Preston JE, Himsworth DT, Worthington VC, Keown M, Michaelis J, et al. Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Ann NY Acad Sci 1998; 854: 37-53.
318. Aldini G, Orioli M, Rossoni G, Savi F, Braidotti P, Vistoli G, et al. The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in Zucker obese rats. J Cell Mol Med 2011; 15: 1339-54.
319. Guiotto A, Calderan A, Ruzza P, Borin G. Carnosine and carnosine-related antioxidants: A review. Curr Med Chem 2005; 12: 2293-315.
320. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: A versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ 2005; 2005: pe12.
321. Yan H, Harding JJ. Carnosine protects against the inactivation of esterase induced by glycation and a steroid. Biochim Biophys Acta 2005; 1741: 120-6.
322. Peterszegi G, Molinari J, Ravelojaona V, Robert L. Effect of advanced glycation end-products on cell proliferation and cell death. Pathol Biol (Paris) 2006; 54: 396-404.
323. Alhamdani MS, Al-Kassir AH, Abbas FK, Jaleel NA, Al-Taee MF. Antiglycation and antioxidant effect of carnosine against glucose degradation products in peritoneal mesothelial cells. Nephron Clin Pract 2007; 107: c26-34.
324. Riedl E, Pfister F, Braunagel M, Brinkkotter P, Sternik P, Deinzer M, et al. Carnosine prevents apoptosis of glomerular cells and podocyte loss in STZ diabetic rats. Cell Physiol Biochem 2011; 28: 279-88.
325. Perez Gutierrez RM, Flores Cotera LB, Gonzalez AM. Evaluation of the antioxidant and anti-glication effects of the hexane extract from Piper auritum leaves in vitro and beneficial activity on oxidative stress and advanced glycation end-product-mediated renal injury in streptozotocin-treated diabetic rats. Molecules 2012; 17: 11897-919.
326. Kim YS, Jung DH, Lee IS, Choi SJ, Yu SY, Ku SK, et al. Effects of Allium victorialis leaf extracts and its single compounds on aldose reductase, advanced glycation end products and TGF-beta1 expression in mesangial cells. BMC Complement Altern Med 2013; 13: 251.
327. Zheng N, Lin X, Wen Q, Kintoko, Zhang S, Huang J, et al. Effect of 2-dodecyl-6-methoxycyclohexa-2, 5-diene-1, 4-dione, isolated from Averrhoa carambola L. (Oxalidaceae) roots, on advanced glycation end-product-mediated renal injury in type 2 diabetic KKAy mice. Toxicol Lett 2013; 219: 77-84.
328. Zhang MH, Feng L, Zhu MM, Gu JF, Jiang J, Cheng XD, et al. The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and High-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats. J Ethnopharmacol 2014; 151: 591-600.
329. Zhang M, Feng L, Gu J, Ma L, Qin D, Wu C, et al. The attenuation of Moutan Cortex on oxidative stress for renal injury in AGEsinduced mesangial cell dysfunction and streptozotocin-induced diabetic nephropathy rats. Oxid Med Cell Longev 2014; 2014: 463815.
330. Yoon J, Lee H, Chang HB, Choi H, Kim YS, Rho YK, et al. DW1029M, a novel botanical drug candidate, inhibits advanced glycation end-product formation, rat lens aldose reductase activity, and TGF-beta1 signaling. Am J Physiol Renal Physiol 2014; 306: F1161-70.
331. Rani MP, Krishna MS, Padmakumari KP, Raghu KG, Sundaresan A. Zingiber officinale extract exhibits antidiabetic potential via modulating glucose uptake, protein glycation and inhibiting adipocyte differentiation: An in vitro study. J Sci Food Agric 2012; 92: 1948-55.
332. Mesias M, Navarro M, Gokmen V, Morales FJ. Antiglycative effect of fruit and vegetable seed extracts: Inhibition of AGE formation and carbonyl-trapping abilities. J Sci Food Agric 2013; 93: 2037-44.
333. Navarro M, Fiore A, Fogliano V, Morales FJ. Carbonyl trapping and antiglycative activities of olive oil mill wastewater. Food Funct 2015; 6: 574-83.
334. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-43.
335. Ishibashi Y, Matsui T, Ohta K, Tanoue R, Takeuchi M, Asanuma K, et al. PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation. Microvasc Res 2013; 85: 54-8.
336. Maeda S, Matsui T, Takeuchi M, Yoshida Y, Yamakawa R, Fukami K, et al. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol Res 2011; 63: 241-8.
337. Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006; 281: 20213-20.
338. Maeda S, Matsui T, Takeuchi M, Yamagishi S. Pigment epithelium-derived factor (PEDF) blocks advanced glycation end products (AGEs)-RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase-mediated oxidative stress generation. Int J Cardiol 2011; 152: 408-10.
339. Yamagishi S, Ueda S, Matsui T, Nakamura K, Imaizumi T, Takeuchi M, et al. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett 2007; 14: 832-5.
340. Ide Y, Matsui T, Ishibashi Y, Takeuchi M, Yamagishi S. Pigment epithelium-derived factor inhibits advanced glycation end productelicited mesangial cell damage by blocking NF-kappaB activation. Microvasc Res 2010; 80: 227-32.
341. Yamagishi S, Matsui T, Takenaka K, Nakamura K, Takeuchi M, Inoue H. Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes Metab Res Rev 2009; 25: 266-71.
342. Kaida Y, Fukami K, Matsui T, Higashimoto Y, Nishino Y, Obara N, et al. DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes 2013; 62: 3241-50.
343. Ojima A, Matsui T, Maeda S, Takeuchi M, Inoue H, Higashimoto Y, et al. DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. Lab Invest 2014; 94: 422-9.
344. Ojima A, Oda E, Higashimoto Y, Matsui T, Yamagishi S. DNA aptamer raised against advanced glycation end products inhibits neointimal hyperplasia in balloon-injured rat carotid arteries. Int J Cardiol 2014; 171: 443-6.
345. Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008; 57: 460-9.
346. Park CH, Noh JS, Fujii H, Roh SS, Song YO, Choi JS, et al. Oligonol, a low-molecular-weight polyphenol derived from lychee fruit, attenuates gluco-lipotoxicity-mediated renal disorder in type 2 diabetic db/db mice. Drug Discov Ther 2015; 9: 13-22.
347. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996; 382: 275-8.
348. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998; 95: 4630-4.
349. Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 2003; 285: H2587-91.
350. Susic D, Varagic J, Ahn J, Frohlich ED. Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats. Am J Hypertens 2004; 17: 328-33.
351. Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 2000; 97: 2809-13.
352. Steppan J, Tran H, Benjo AM, Pellakuru L, Barodka V, Ryoo S, et al. Alagebrium in combination with exercise ameliorates age associated ventricular and vascular stiffness. Exp Gerontol 2012; 47: 565-72.
353. Shapiro BP, Owan TE, Mohammed SF, Meyer DM, Mills LD, Schalkwijk CG, et al. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. Circulation 2008; 118: 1002-10.
354. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. Faseb J 2003; 17: 1762-4.
355. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-92.
356. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004; 53: 1813-23.
357. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, et al. Accelerated nephropathy in diabetic apolipoprotein eknockout mouse: Role of advanced glycation end products. J Am Soc Nephrol 2004; 15: 2125-38.
358. Vaitkevicius PV, Lane M, Spurgeon H, Ingram DK, Roth GS, Egan JJ, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 2001; 98: 1171-5.
359. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product crosslink breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004; 53: 2921-30.
360. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11: 191-5.
361. Zieman SJ, Melenovsky V, Clattenburg L, Corretti MC, Capriotti A, Gerstenblith G, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 2007; 25: 577-83.
362. Brodeur MR, Bouvet C, Bouchard S, Moreau S, Leblond J, Deblois D, et al. Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes. PLoS One 2014; 9: e85922.
363. Willemsen S, Hartog JW, Hummel YM, Posma JL, van Wijk LM, van Veldhuisen DJ, et al. Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. Eur J Heart Fail 2010; 12: 294-300.
364. Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 2011; 13: 899-908.
365. Fujimoto N, Hastings JL, Carrick-Ranson G, Shafer KM, Shibata S, Bhella PS, et al. Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals. Circ Heart Fail 2013; 6: 1155-64.
366. Oudegeest-Sander MH, Olde Rikkert MG, Smits P, Thijssen DH, van Dijk AP, Levine BD, et al. The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: A randomized factorial design trial. Exp Gerontol 2013; 48: 1509-17.
367. Cheng G, Wang LL, Long L, Liu HY, Cui H, Qu WS, et al. Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats. Br J Pharmacol 2007; 152: 1196-206.
368. Joshi D, Gupta R, Dubey A, Shiwalkar A, Pathak P, Gupta RC, et al. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol 2009; 54: 72-81.
369. Chandra KP, Shiwalkar A, Kotecha J, Thakkar P, Srivastava A, Chauthaiwale V, et al. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: Safety, tolerability and pharmacokinetics in healthy subjects. Clin Drug Investig 2009; 29: 559-75.